use of mehamudgara rasa in diabetic neuropathy

RANDOMIZED CONTROLLED CLINICAL STUDY TO EVALUATE THE EFFICACY OF MEHA-MUDGARA RASA IN THE MANAGEMENT OF MADHUMEHJANYA NADIPRATHAN SHOTHA W.R.T DIABETIC NEUROPATHYâ??

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/07/020275

Enrollment

100

Registered

2019-07-19

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E114- Type 2 diabetes mellitus with neurological complications

Interventions

Intervention1: Meha Mudagara Rasa: 500 mg BD ORALLY FOR 1 MONTH Control Intervention1: Tab. PREGALIN: ( Pragabalin 75 mg ) 1 Tab. OD ORALLY FOR 1 MONTH

Eligibility

Inclusion criteria

Inclusion criteria: 1) Patients with clinical positive history of type 2 diabetes mellitus having the symptoms of diabetic neuropathy (peripheral) are selected for the present study 2) NDS score between 3 to 8 will be included 3)abnormal vibration perception study will be included

Exclusion criteria

Exclusion criteria: ï?§ The cases with complications like diabetic gangrene, carbuncles, diabetic coma, retinopathy, IDDM will be excluded from present clinical trials. ï?§ Any major diseases like Kochâ??s, IHD, AIDS etc associated with diabetes mellitus. ï?§ Thyroid dysfunction, Patients on Corticosteroid Therapy

Design outcomes

Primary

Measure	Time frame
To evaluate clinical Efficacy of Meha-Mudgara Rasa in the management of Madhumehajanya Nadipratan Shotha w.r.t Diabetes NeuropathyTimepoint: Initial Day 1st day, 10th day, 20th day ,30th day	—

Secondary

Measure	Time frame
to compare the clinical outcomes of both the group viz .mehamudgara rasa & pregabalinTimepoint: 1yr	—

Countries

India

Contacts

Public ContactDr Dnyaneshwar Padavi

School of Ayurveda, D. Y. Patil Deemed to be University

dmpadavi@gmail.com9833158688

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026